Stocks Overview

LAST PRICE
42.4700
TODAY'S CHANGE (%)
Trending Down-1.9600 (-4.4114%)

Bid / Lots
40.0000/ 1
Ask / Lots
68.1200/ 2
Open / Previous Close
44.3500 / 44.4300
Day Range
Low 42.4000
High 44.5250
52 Week Range
Low 19.7950
High 53.2850
Volume
590,200
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Monday's close: 44.43
Time	Volume	AGIO
09:32 ET	3699	44.525
09:34 ET	3200	44
09:36 ET	1500	43.28
09:38 ET	1450	43.39
09:39 ET	6403	43.18
09:41 ET	300	43.32
09:43 ET	1000	43.01
09:45 ET	1000	43.03
09:48 ET	3180	43.13
09:50 ET	1100	43.14
09:52 ET	9937	43.4
09:54 ET	1945	43.25
09:56 ET	1749	43.38
09:57 ET	1100	43.37
09:59 ET	798	43.6
10:01 ET	2698	44.01
10:03 ET	900	44.07
10:06 ET	324	44.17
10:08 ET	1500	43.81
10:10 ET	500	43.82
10:12 ET	1601	43.56
10:15 ET	100	43.51
10:17 ET	100	43.38
10:19 ET	900	43.26
10:24 ET	1700	43.39
10:26 ET	550	43.34
10:28 ET	5336	43.365
10:30 ET	100	43.33
10:32 ET	1450	43.432
10:33 ET	2543	43.22
10:35 ET	1401	43.29
10:37 ET	300	43.32
10:39 ET	807	43.3
10:42 ET	900	43.185
10:44 ET	2249	43.23
10:46 ET	300	43.17
10:48 ET	916	43
10:50 ET	615	43
10:51 ET	613	42.975
10:53 ET	2260	42.9
10:55 ET	2394	42.945
10:57 ET	500	42.91
11:00 ET	2229	42.98
11:02 ET	1700	42.93
11:04 ET	642	42.88
11:06 ET	300	42.815
11:08 ET	1250	42.68
11:09 ET	200	42.64
11:11 ET	1000	42.71
11:13 ET	1955	42.725
11:15 ET	1700	42.785
11:18 ET	500	42.67
11:20 ET	200	42.71
11:22 ET	6298	42.6
11:24 ET	1689	42.73
11:26 ET	1271	42.59
11:27 ET	500	42.74
11:29 ET	673	42.7
11:31 ET	686	42.905
11:33 ET	100	42.885
11:36 ET	200	42.985
11:38 ET	2523	42.945
11:40 ET	732	42.955
11:42 ET	2040	42.835
11:44 ET	300	42.77
11:45 ET	1707	42.84
11:47 ET	400	42.835
11:49 ET	754	42.84
11:51 ET	200	42.85
11:54 ET	300	42.86
11:56 ET	500	42.905
11:58 ET	200	42.93
12:00 ET	400	42.975
12:02 ET	2024	42.86
12:03 ET	1100	43.04
12:05 ET	300	43.125
12:07 ET	100	43.195
12:09 ET	100	43.215
12:12 ET	700	43.23
12:14 ET	3900	43.39
12:16 ET	700	43.28
12:18 ET	100	43.36
12:20 ET	1006	43.37
12:21 ET	200	43.44
12:23 ET	100	43.49
12:25 ET	100	43.48
12:27 ET	300	43.495
12:30 ET	2268	43.42
12:32 ET	100	43.41
12:36 ET	1900	43.49
12:38 ET	200	43.56
12:39 ET	400	43.39
12:41 ET	700	43.41
12:43 ET	100	43.36
12:45 ET	500	43.365
12:48 ET	600	43.16
12:52 ET	100	43.18
12:54 ET	500	43.31
12:56 ET	400	43.34
12:57 ET	1924	43.485
01:01 ET	100	43.51
01:03 ET	3209	43.41
01:06 ET	100	43.42
01:08 ET	1785	43.23
01:10 ET	100	43.22
01:12 ET	200	43.22
01:14 ET	100	43.265
01:15 ET	100	43.255
01:17 ET	709	43.188
01:19 ET	100	43.14
01:21 ET	200	43.17
01:24 ET	405	43.13
01:26 ET	300	43.03
01:30 ET	2534	42.98
01:32 ET	100	43
01:33 ET	1350	43.11
01:37 ET	700	42.99
01:39 ET	508	42.93
01:44 ET	100	42.975
01:46 ET	800	43.06
01:48 ET	200	43.055
01:50 ET	9476	43.24
01:51 ET	1500	43.01
01:55 ET	300	43.07
01:57 ET	500	43.085
02:00 ET	384	43.16
02:02 ET	900	43.12
02:04 ET	1000	43.13
02:06 ET	201	43.1
02:09 ET	4540	43.19
02:11 ET	1376	43.23
02:13 ET	200	43.23
02:15 ET	1000	43.31
02:18 ET	500	43.39
02:20 ET	1100	43.31
02:22 ET	300	43.31
02:24 ET	800	43.23
02:26 ET	2150	43.18
02:27 ET	861	43.115
02:29 ET	100	43.115
02:31 ET	1100	43.14
02:33 ET	300	43.13
02:36 ET	610	43.09
02:38 ET	1200	43
02:40 ET	100	43
02:42 ET	100	42.97
02:44 ET	200	43.03
02:45 ET	1150	43.055
02:47 ET	418	43.115
02:49 ET	500	43.17
02:51 ET	2400	43
02:54 ET	900	42.89
02:56 ET	2400	42.795
02:58 ET	1947	42.8
03:00 ET	1300	42.805
03:02 ET	2537	42.71
03:03 ET	1000	42.91
03:05 ET	3182	42.955
03:07 ET	1179	42.85
03:09 ET	400	42.915
03:12 ET	673	42.92
03:14 ET	200	42.95
03:16 ET	1302	42.86
03:18 ET	4784	42.75
03:20 ET	370	42.805
03:21 ET	1200	42.695
03:23 ET	2684	42.71
03:25 ET	100	42.68
03:27 ET	369	42.765
03:30 ET	16976	42.77
03:32 ET	1200	42.65
03:34 ET	900	42.72
03:36 ET	1200	42.715
03:38 ET	600	42.805
03:39 ET	2442	42.76
03:41 ET	403	42.73
03:43 ET	8340	42.61
03:45 ET	4055	42.55
03:48 ET	1100	42.625
03:50 ET	5380	42.505
03:52 ET	3957	42.49
03:54 ET	5392	42.52
03:56 ET	13422	42.53
03:57 ET	9330	42.44
03:59 ET	100730	42.47

Data delayed at least 15 minutes.

Sep 27, 2024
- DJ Agios Pharmaceuticals Down Over 6%, on Pace for Largest Percent Decrease Since September 2022 -- Data Talk, from 1:36PM ET on Friday Sep 27, 2024 by Dow Jones
  1:36PM ET on Friday Sep 27, 2024 by Dow Jones
- DJ Agios Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners, from 7:40AM ET on Friday Sep 27, 2024 by Dow Jones
  7:40AM ET on Friday Sep 27, 2024 by Dow Jones
Sep 19, 2024
- DJ Agios Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 9:18AM ET on Thursday Sep 19, 2024 by Dow Jones
  9:18AM ET on Thursday Sep 19, 2024 by Dow Jones
Sep 11, 2024
- DJ Agios Gets FDA Orphan Designation for Tebapivat in Myelodysplastic Syndromes, from 7:28AM ET on Wednesday Sep 11, 2024 by Dow Jones
  7:28AM ET on Wednesday Sep 11, 2024 by Dow Jones
- Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS), from 7:00AM ET on Wednesday Sep 11, 2024 by Dow Jones
  7:00AM ET on Wednesday Sep 11, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesAGIO Agios Pharmaceuticals Inc	2.5B	-6.5x	---
United StatesIDYA IDEAYA Biosciences Inc	2.7B	-14.1x	---
United StatesCGON CG Oncology Inc	2.5B	-31.6x	---
United StatesGPCR Structure Therapeutics Inc	2.5B	-18.9x	---
United StatesEWTX Edgewise Therapeutics Inc	2.5B	-17.8x	---
United StatesIBRX Immunitybio Inc	2.6B	-3.8x	---
As of 2024-10-01

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.

Contact Information

Headquarters: 88 Sidney StreetCAMBRIDGE, MA, United States 02139
Phone: 617-649-8600
Fax: 302-655-5049

Executives

Chairman of the Board: Jacqualyn Fouse
Chief Executive Officer, Director: Brian Goff
Chief Financial Officer: Cecilia Jones
Chief Legal Officer: James Burns
Chief Medical Officer, Head - Research and Development: Sarah Gheuens

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$2.5B
Revenue (TTM)	$31.3M
Shares Outstanding	56.9M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	0.75
EPS	$-6.49
Book Value	$14.50
P/E Ratio	-6.5x
Price/Sales (TTM)	80.7
Price/Cash Flow (TTM)	---
Operating Margin	-1,293.88%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Agios Pharmaceuticals Inc
NASDAQ:AGIOUnited States

Search Criteria

Charts

Recent News

Sep 27, 2024

DJ Agios Pharmaceuticals Down Over 6%, on Pace for Largest Percent Decrease Since September 2022 -- Data Talk, from 1:36PM ET on Friday Sep 27, 2024 by Dow Jones

DJ Agios Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners, from 7:40AM ET on Friday Sep 27, 2024 by Dow Jones

Sep 19, 2024

DJ Agios Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 9:18AM ET on Thursday Sep 19, 2024 by Dow Jones

Sep 11, 2024

DJ Agios Gets FDA Orphan Designation for Tebapivat in Myelodysplastic Syndromes, from 7:28AM ET on Wednesday Sep 11, 2024 by Dow Jones

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS), from 7:00AM ET on Wednesday Sep 11, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar